Pfizer has relieving news for the world. The global struggle against the COVID-19 has continued for more than a year, yet vaccine producer Pfizer has started the 2nd and 3rd phase clinical trials of a drug that will prevent infection from the virus. The latest situation of the drug trials against the coronavirus catch a lot of attention.
“Proper medication MUST BE DEVELOPED IN ADDITION TO THE VACCINE.”
According to Pfizer’s statement, clinical trials of the antiviral drug will be conducted on 2660 healthy adults aged 18+ living in the same household with people who have coronavirus and showing symptoms. Mikael Dolsten, Head of Global Research, Development and Medicine at Pfizer, said: “We believe that in the global fight against COVID-19, we believe that it is necessary to develop effective treatments for people who have been caught or exMetin girmek için buraya tıklayın veya dokunun.posed to the virus, along with the vaccine that control the infection.”
The medication will be used with the same subtance used in HIV infections
Dolsten stated that if the drug tested is successful, it will stop the virus before it has the opportunity to multiply and prevent the development of symptoms in those who are infected.
It has been announced that the drug, which aims to stop the production of an enzyme that allows the COVID-19 virus to multiply, will be used together with ritonavir, which is widely used in HIV infections.
Prior to Pfizer, US-based Merck and Swedish pharmaceutical company Roche also announced that they were developing pill-format drugs for the prevention and treatment of coronavirus infection.